



**AGENDA**  
**FDA Virtual Public Workshop**

**Nitrosamines as Impurities in Drugs; Health Risk Assessment and Mitigation  
Workshop**

**March 29 – 30, 2021**

**Scope/Objectives:**

The objectives of this workshop is to gather scientific information on nitrosamines. A panel of national and international experts is invited to discuss the current thinking on the toxicity and chemistry of nitrosamines and, to deliberate on the most appropriate approaches to the safety assessment when nitrosamine formation and presence in drug products cannot be avoided. In addition, the experts are asked to identify data gaps and / or research needs to address the uncertainties in nitrosamine safety assessment.

**Day 1 Agenda**  
**9:00-2:45pm EST**

<b>Time</b>	<b>Topic</b>	<b>Speaker(s) and Affiliation</b>
9:00 AM – 9:10 AM	Purpose and Goals of the workshop	Dr. Aisar Atrakchi, FDA
9:10 AM – 9:50 AM	N-Nitroso compounds in the human environment: Lessons and issues	Dr. Gerhard Eisenbrand, University of Kaiserslautern, Germany
9:50 AM – 10:10 AM	Nitrosamine Contamination of Drug Products	Dr. Sruthi King, FDA
10:10 AM – 11:30 AM	<b>Questions for the Panelists</b>  <u>Exposure and Risk Assessment</u>  1. What are the endogenous levels of nitrosamine formation in humans and rodents? Once formed, what is the	Panelists

	<p>rate/kinetics of elimination? What are the conversion rates in the liver, circulation levels in blood, and, normal variations? If this information is not available, can it be determined experimentally?</p> <p>2. Can nitrosamines be classified? If yes, what is the basis of their classification? e.g. could they be classified based on:</p> <ul style="list-style-type: none"> <li>➤ Carcinogenic potency?</li> <li>➤ Chemical structure e.g. aliphatic vs. cyclic?</li> <li>➤ Chemical reactivity? Direct alkylating agents vs. indirect (require metabolism)? Adduct formed e.g. O6- , O7- methylation?</li> <li>➤ Other</li> <li>➤ Why would you choose this basis of classification?</li> </ul> <p>If classification is not possible, is it feasible to calculate a “single” Acceptable Intake (AI) value for nitrosamines i.e. Class Specific Limit, using the existing carcinogenicity study results of 110+ nitrosamines (irrespective of study quality)?</p>	
11:30 AM – 11:40 AM	<b>Break</b>	
11:40 AM – 12:30 PM	<p>3. The carcinogenic potential of nitrosamines is dose and duration dependent;</p> <ul style="list-style-type: none"> <li>➤ Is there an in vivo exposure level for nitrosamines that could define low vs high risk for carcinogenicity? Is it appropriate to calculate a NOEL dose for carcinogenicity? What are the</li> </ul>	Panelists

	<p>criteria to do so (Ames negative, in vivo mutation assay negative, other)?</p> <ul style="list-style-type: none"> <li>➤ Can a less than lifetime (LTL) approach as described in ICH M7 Guidance be used to determine the AI, of a nitrosamine if a drug is indicated for a short duration of use?</li> </ul>	
12:30 PM – 1:00 PM	<b>Lunch</b>	
1:00 PM – 2:45 PM	4. How would the risk assessment change when multiple nitrosamines are present in a drug product? What are the key variables to consider when conducting such risk assessment? (nonmutagenic carcinogen + mutagenic carcinogen; nonmutagenic carcinogen + weakly mutagenic carcinogen; multiple mutagenic carcinogens, etc.)	Panelists
2:45 PM	Adjourn	FDA

**Day 2 Agenda**  
**9:00-2:30pm EST**

<b>Time</b>	<b>Topic</b>	<b>Speaker(s) and Affiliation</b>
9:00 AM – 9:05 AM	Welcome/Introduction to Day 2	Aisar Atrakchi, FDA
9:05 AM – 11:00 AM	<p><u>Exposure and Risk Assessment</u></p> <p>5. Should the regulatory limits for nitrosamines listed for food and water or, amount formed endogenously, be considered in determining AI of nitrosamines in drugs?</p>	Panelists



	<u>Chemistry</u> 6. In the absence of data and based on identified differences in nitrosamine chemistries and reactivities, can read-across for structural similarity to related compounds be used for nitrosamines? What are the key parameters to consider when conducting (Q)SAR assessment for nitrosamines?	
11:00 AM – 11:10 AM	<b>Break</b>	
11:10 AM – 12:30 PM	7. Nitrosamines can be formed during manufacturing of the Active Pharmaceutical Ingredient (API), and/or Drug Product (DP). What are possible approaches to consider in order to reduce nitrosamine formation during manufacturing? Can nitrosamines be eliminated completely from API and/or DP?	Panelists
12:30 PM – 1:00 PM	<b>Lunch</b>	
1:00 PM – 2:00 PM	Continue Discussions	Panelists
2:00 PM	Questions from Attendees, Summary and Conclusion	FDA
2:30 PM	Adjourn	FDA



Speaker slides and other workshop materials can be found here before and after the meeting (please check for regular updates): <https://www.fda.gov/drugs/news-events-human-drugs/nitrosamines-impurities-drugs-health-risk-assessment-and-mitigation-public-workshop-03292021>

### Meeting Platform Links:

#### DAY I:

**Date and time:** Monday, March 29, 2021 9:00 am Eastern Daylight Time (New York, GMT-04:00)

**Event address:** <https://fda1.webex.com/fda1/onstage/g.php?MTID=e97716c9653fcfeb9bb17a1b836c6917c>

**Event number:** 199 720 8735

**Event password:** CDymqSBp479

**Audio conference:** To receive a call back, provide your phone number when you join the event, or call the number below and enter the access code.

**US Toll Free:** +1-877-465-7975

**US Toll:** +1-210-795-0506

[Show all global call-in numbers](#)

[Show toll-free dialing restrictions](#)

**Access code:** 199 720 8735

---

#### DAY II:

**Date and time:** Tuesday, March 30, 2021 9:00 am Eastern Daylight Time (New York, GMT-04:00)

**Event address:** <https://fda1.webex.com/fda1/onstage/g.php?MTID=e3118a9b24928a0f94607dbb6bfadb1ae>

**Event number:** 199 029 8320

**Event password:** eTmReeTA353

**Audio conference:** To receive a call back, provide your phone number when you join the event, or call the number below and enter the access code.

**US Toll Free:** +1-877-465-7975

**US Toll:** +1-210-795-0506

[Show all global call-in numbers](#)

[Show toll-free dialing restrictions](#)

**Access code:** 199 029 8320